Nivolumab/Relatlimab
- Generic Name
- Nivolumab/Relatlimab
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: mRNA-4106
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT06880536
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: mRNA-4106
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT06880549
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
- Conditions
- MelanomaUnresectable Melanoma
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 69
- Registration Number
- NCT05428007
- Locations
- 🇺🇸
The Angeles Clinic at Cedars Sinai, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05134948
- Locations
- 🇨🇳
Local Institution - 0001, Beijing, Beijing, China
🇨🇳Local Institution - 0002, Fuzhou, Fujian, China
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
- Conditions
- Gastric CancerCancer of the StomachEsophagogastric Junction
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 274
- Registration Number
- NCT03662659
- Locations
- 🇩🇪
Local Institution - 0014, Frankfurt, Germany
🇺🇸Local Institution - 0040, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
- Conditions
- Neoplasms by Site
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1499
- Registration Number
- NCT01968109
- Locations
- 🇺🇸
Local Institution - 0002, Portland, Oregon, United States
🇯🇵Local Institution - 0052, Chuo-ku, Tokyo, Japan
🇺🇸Local Institution - 0043, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.